skip to Main Content

MaRS Innovation Statement on 2014 Ontario Budget

TORONTO, ON (May 2, 2014) – MaRS Innovation congratulates the government’s deepened commitment to support the life sciences through research and innovation funding. In particular, the new $30 million Life Sciences Seed Venture Capital Fund will create a partnership between the Province of Ontario, the private sector and hospital foundations to finance Ontario-based life sciences companies.

Dr. Raphael Hofstein
Dr. Raphael Hofstein, president & CEO, MaRS Innovation.

“As co-designers of this venture capital fund and one of its many champions, MaRS Innovation welcomes this news,” says Dr. Raphael (Rafi) Hofstein, president and CEO. “We look forward to the strong collaborations it will foster with our colleagues in the Government of Ontario, private industry and the hospital community.”

“By their nature and the need for regulation, life sciences companies take considerable time to mature products and their underlying technologies. Expanding the funding available during this critical stage through this unique public-private partnership will give more Ontario start-ups emerging with disruptive technologies from the province’s academic institutions the financing they need to succeed and thrive,” says Hofstein.

Continue Reading

Baxter and MaRS Innovation Form Strategic Partnership

Partnership to invest up to $1M in promising Canadian healthcare discoveries

Baxter Corporate Headquarters in Mississauga, ON
Baxter Corporate Headquarters in Mississauga, ON

TORONTO, Ontario, October 4, 2012—Baxter International Inc. and MaRS Innovation, a Centre of Excellence for Commercialization and Research, have entered into a strategic partnership to commercialize early-stage technologies that present innovative methods in therapeutics and drug discovery technologies.

Information about Baxter and MaRS Innovation’s partnership is also available in French.

The partnership’s shared vision for delivering novel, transformative therapeutic technologies will benefit Canadians and others around the world. Baxter and MaRS Innovation will identify investment opportunities emerging from well-validated scientific research discoveries within MaRS Innovation’s 16 member institutions, including the University of Toronto and its nine affiliated teaching hospitals.

Continue Reading
Back To Top